Compare AbbVie Inc (ABBV) vs GE Vernova Inc (GEV) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.

AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.

GE Vernova (GEV) trades at $1,152.04, up 3.5% with strong bullish technical signals and robust fundamentals. The stock shows impressive profitability with 23.81% net margin and 83.23% ROE, though valuations appear elevated with P/E of 33.67. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q2 2026 estimates await. The company benefits from AI infrastructure demand, with gas turbines powering data centers driving growth.

Outlook remains positive given AI-driven power infrastructure demand and raised 2026 guidance, but premium valuation and execution risks warrant caution. Analyst consensus strongly favors buying with $1,220 price target, representing 6% upside. Key risks include valuation sensitivity and competitive pressures in energy transition markets.